Eckert & Ziegler SE
ISIN: DE0005659700
WKN: 565970
13 December 2024 09:00AM

EQS-News: Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2050215

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Admission/Market Launch
Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW

13.12.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 13 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan.

GalliaPharm® is widely used as a high-quality GMP grade generator for Gallium-68, supporting the production of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in oncology including the diagnosis of prostate cancer through PSMA imaging. An approval in Japan will provide the local healthcare community with an accessible and reliable tool to label Gallium-68 radiopharmaceuticals, offering new precision in diagnostic imaging that may improve early disease detection and patient outcomes.

“This step with the MHLW for us is a critical one,” stated Dr. Deljana Werner, Head of QA and Regulatory Affairs for the Medical Division of Eckert & Ziegler SE. “As a company committed to advancing nuclear medicine globally, we see GalliaPharm®’s entry into the Japanese market as a pivotal opportunity to support medical professionals in enhancing patient care through precise and innovative imaging solutions.”

By seeking approval in Japan, Eckert & Ziegler reinforces its commitment to meeting the specific needs of diverse healthcare markets, tailoring its innovations to support local advancements in nuclear medicine. This step not only underscores the company’s dedication to providing advanced radioisotopes for medical applications worldwide, but also strengthens its position as a trusted partner in the evolving landscape of radiopharmaceuticals.

About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact

Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; https://ezag.com



13.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2050215

 
End of News EQS News Service

2050215  13.12.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2050215&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 168,71 178,49 176,14 180,44 222,26 246,09 290,00
EBITDA1,2 32,14 43,13 44,64 57,04 55,52 58,83 0,00
EBITDA-Margin3 19,05 24,16 25,34 31,61 24,98 23,91 0,00
EBIT1,4 23,39 32,06 33,69 47,45 44,54 45,45 60,00
EBIT-Margin5 13,86 17,96 19,13 26,30 20,04 18,47 20,69
Net Profit (Loss)1 16,89 22,48 23,11 34,66 29,75 26,77 0,00
Net-Margin6 10,01 12,60 13,12 19,21 13,39 10,88 0,00
Cashflow1,7 21,21 40,43 36,79 33,86 34,30 47,40 0,00
Earnings per share8 0,78 1,07 1,11 1,66 1,41 1,26 1,54
Dividend per share8 0,30 0,42 0,45 0,50 0,50 0,05 0,50
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Forvis Mazars

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Eckert & Ziegler
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
565970 DE0005659700 SE 943,84 Mio € 25.05.1999 Halten 9F4MJGG3+WR
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
27,52 26,29 1,05 49,04 4,27 19,91 3,84
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,50 0,05 0,50 1,12%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
18.06.2025 13.05.2025 08.08.2025 14.11.2024 27.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,41%
44,58 €
ATH 141,40 €
+5,41% +14,32% +21,44% +24,09% +675,30%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL